drugset
drugset / Trial / NCT05899738

A Study to Compare the Relative Bioavailability of Two Iberdomide (CC-220) Formulations and to Assess The Effect Of Food on the Drug Levels of Iberdomide in Healthy Adult Participants

NCT05899738 ↗

Phase 1 Completed 32 enrolled Bristol-Myers Squibb Celgene Corporation · collab
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to evaluate the relative bioavailability for the new iberdomide powder for reconstitution formulation relative to the reference capsule formulation and to assess the effect of food on the pharmacokinetics of powder for reconstitution formulation in healthy adult participants.

Timeline

Start
2023-05-18
Primary completion
2023-07-06
Completion
2023-07-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Iberdomide Small molecule — —

Indications

No indication recorded.